ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose All Languages Europe Asia Pacific North America Latin America close Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Turkey United Kingdom Korea (HQ) Korea (EN) Japan Australia Canada (EN) Canada (FR) USA Brazil Colombia Chile Peru Mexico
Category IR Approvals General Other All Title Content delete search IR Notification Regarding Review Results of Merger Proposal 2024.08.16 Top-pinned content General Latest Updates on Agreements with PBMs for Zymfentra 2024.08.05 Top-pinned content IR Collecting shareholder’s opinions to examine whether to proceed with the merger with Celltrion Pharm 2024.07.31 Top-pinned content IR Notification Regarding Review Results of Merger Proposal 2024.08.16 General Latest Updates on Agreements with PBMs for Zymfentra 2024.08.05 General Responses to Inquiries regarding the Inclusion of Zymfentra in PBM Formularies 2024.08.01 IR Collecting shareholder’s opinions to examine whether to proceed with the merger with Celltrion Pharm 2024.07.31 General Latest Developments Regarding the Agreement with PBMs for Yuflyma 2024.04.11 General Response to Inquiries Regarding the Inclusion of Zymfentra in PBM Formularies 2024.04.08 General Notice to shareholders 2022.09.15 General Notice to shareholders regarding: The conclusion of the financial regulator’s audit inspection and the Securities & Futures Commission’s review 2022.03.11 General Celltrion’s Statement on the development of a therapeutic antibody treatment to combat COVID-19 2020.04.13 General Celltrion receives EIR from the FDA 2018.09.18 First 1 2 Last